PLX - AMEX
Protalix BioTherapeutics, Inc.
$2.01
+1.8%Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
At a Glance
Live Snapshotplx
Cash at End of Period
Last Annual Value
15.38M
3-Year CAGR
-3%
5-Year CAGR
-3%
10-Year CAGR
-15%
Protalix BioTherapeutics, Inc. Competitors Analysis of Cash at End of Period
| Company | Cash at End of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Protalix BioTherapeutics, Inc. AMEX:PLX | 15.38M | -13.3% | -17.0% | -13.2% | |
 Sangamo Therapeutics, Inc. NASDAQ:SGMO | 20.95M | -23.5% | -35.0% | -0.5% | |
 SELLAS Life Sciences Group, Inc. NASDAQ:SLS | 71.89M | 201.2% | 27.4% | 14.8% | |
 Coherus Oncology, Inc. NASDAQ:CHRS | 89.12M | -4.7% | -26.6% | -3.3% | |
 Neonc Technologies Holdings, Inc. NASDAQ:NTHI | 58.73K | 22.6% | 18.6% | N/A | |
 Invivyd, Inc. NASDAQ:IVVD | 226.69M | 4.2% | -16.0% | N/A | |
 Codexis, Inc. NASDAQ:CDXS | 52.88M | -7.4% | -15.0% | 10.6% | |
 Protara Therapeutics, Inc. NASDAQ:TARA | 50.40M | 7.7% | 6.7% | 3.3% | |
 OmniAb, Inc. NASDAQ:OABI | 26.08M | 15.5% | N/A | N/A |
Protalix BioTherapeutics, Inc. Fair Value Envelope
Related Guides
Continue your PLX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.